Several months after forging a fresh path forward for its troubled Friedreich ataxia (FA) drug vatiquinone, PTC Therapeutics ...

Additionally, PTC analyzed long-term open-label data from an earlier study of vatiquinone in adults with FA. Following 24-months of treatment with vatiquinone, subjects had a 4.8-point benefit on the ...

Larimar Therapeutics' CTI-1601 offers hope for Friedreich's ataxia patients, with promising trial results. Check out why LRMR ...

Most people haven’t heard of the condition, but Friedreich’s ataxia is getting more attention because of a new treatment and ...

Panelists discuss how the differential diagnosis for Friedreich's Ataxia involves distinguishing it from other ataxias, the ...

There is currently no cure for Friedreich’s ataxia. Treatment focuses on managing your symptoms and improving your quality of life to help you maintain your daily function and activities as long ...

In order to improve the quality of life of patients with the Ataxia disease, the biotechnological and pharmaceutical industry ...

Genetic analysis beyond the causative variants, and independent of the core clinical symptoms (pyramidal signs versus ataxia), might offer a more pertinent way to approach phenotypic variability.

With fresh, positive data in hand, Biohaven now believes its medicine could be the first to receive FDA approval for spinocerebellar ataxia.

Shares of Biohaven climbed 13% premarket on Monday after the biotech company said its treatment for a rare neurological ...

Biohaven said its experimental treatment for a rare neurological condition showed "a robust and clinically meaningful" ...

Biohaven Ltd. reported positive results from a pivotal study using troriluzole for the treatment of patients with ...